Does renal impairment meaningfully affect exposure to intravenous daratumumab in patients with multiple myeloma?

No clinically important differences in intravenous daratumumab exposure were observed in multiple myeloma patients with mild, moderate or severe renal impairment or end-stage renal disease versus normal renal function in four population pharmacokinetic analyses, although no formal renal-impairment studies were conducted.